In my role as a hospital manager I am still challenged to reach this goal everyday. Many years of experience in a leadership position do not guarantee the mastering of a perfect management style. One of the reasons for this is the need for continuous change. You have to adapt your leadership style and position as the values of staff members change...
READ MOREPresident of EAHM, Mr. Heinz Kölking welcomed members to the General Assembly and started by saying a few words about our dear colleague and long-standing EAHM member Asger Hansen who passed away in 2011. After a moment of silence the General Assembly got underway. Zurich 2010.This year’s agenda and the minutes from the 40th Ordinary General Assembly...
READ MOREThe morning section focused on current European health policy with a keynote presentation by Mars Di Bartolomeo, Minister of Health and Social Affairs, Luxembourg.The afternoon was devoted to the EU Directiveon Patients’ Rights and its impacton hospitals. The key presentation was given by Annika Nowak, European Commission and was followed by comments...
READ MORELast October in Venice, Italy, 16 European professional and scientific societies from 14 countries involved ininfection prevention and control formed EUNETIPS- a European network to promote infection prevention forpatient safety. The goal of EUNETIPS to promote better cooperation among nations, to share experiences,to promote and support initiatives...
READ MORE2011 Saw the Start of Your Mandate of President of EAHM. How was Your First Year in Charge and What did You Accomplish? As I have been active member of the association (Board and Executive Committee) for a long time now there is a certain continuity within the Presidency. The main activities of my Presidency focus on the implementation of the results...
READ MOREThe rapid growth of pharmaceutical expenditure driven by changing demographics, strict clinical targets, rising patient expectations and the continued launch of new expensive drugs has become a contentious issue in the healthcare sector. New expensive drugs include new biological drugs marketed at considerably higher costs than previous standards,...
READ MORETo acheive marketing approval, a molecule undergoes different development phases and a variety of studies need to be carried out. A new molecule typically involves preclinical testing in animals followed by clinical trials in humans, after which the application is submitted to regulatory agencies for review. In case of new delivery system,...
READ MOREIT @ Networking Awards 2012 - 3rd Place The LV Prasad Eye Institute (LVPEI) was established in 1986-87 at Hyderabad as a not-for-profit, nongovernment, public-spirited, comprehensive eye care institution. From its very beginning, it set forth as its core values the “Three E’s”: Equity, Efficiency and Excellence. Equity translates as treating...
READ MOREAll licensed drugs have trial evidence that they work within their licensed indications, otherwise they would not have been granted a marketing authorisation by bodies such as the European Medicines Agency. Nevertheless they do not necessarily have to work particularly well or sufficiently well to justify their cost compared with other available...
READ MOREChallenges, Plans and Solutions Norway faces the same dilemma of many western European countries, as the standard of living improves and people’s life expectancy increases, there are new challenges with an ageing population and a growing number of people with chronic diseases. An ageing society will be a challenge for the Norwegian healthcare...
READ MORE